(Press-News.org) In a major new study, researchers from Intermountain Health in Salt Lake City have found that weight loss drugs used by patients who have high triglycerides do not increase their risk of pancreatitis or adverse cardiac events.
Since the first GLP-1 receptor agonists (GLP1RAs), more commonly known now as weight loss drugs, were approved in 2005, some clinicians have been hesitant to prescribe them to people who have very high triglycerides. That’s because these patients are typically at high risk of pancreatitis, and the drugs interact with the pancreas.
In the new study, Intermountain researchers found that GLP1RAs don’t increase the risk of pancreatitis in these patients – and for those who have never had pancreatitis, being on a GLP1RA medication led to a four times lower risk of developing the condition.
“Pancreatitis is incredibly painful and can be deadly. Once you have a patient with acute pancreatitis you want no part of causing it again,” said Leslie Iverson, PA-C, cardiovascular prevention and research clinician at Intermountain Health. “But these findings show no link between pancreatitis and patients with high triglycerides taking a weight loss drug. Even better, we found that these drugs may offer protection against ever having it in the first place.”
Study findings were presented at the American Heart Association Scientific Sessions 2025 in New Orleans on Nov. 9.
In the retrospective study, Intermountain researchers reviewed the electronic health records of patients treated at Intermountain Health between January 2006 and April 2025 and identified patients over 18 years old with Type 2 diabetes and/or a body mass index over 27.
One of the key factors researchers included in their analysis was whether a patient had severe hypertriglyceridemia (HTG), with a triglyceride level over 500.
Severe HTG is a known risk factor for pancreatitis, which is why physicians may be less likely to prescribe GLP1RA medications to patients with the condition.
Of the 346,667 patients reviewed in the study, 3,834 (1.1%) were prescribed a GLP1RA medication. Overall, researchers found no increased risk of pancreatitis in patients prescribed a GLP1RA medication.
They also found no increased risk of pancreatitis in patients with HTG, including those with a triglyceride level over 500.
For those patients with HTG who never had pancreatitis before, they had a four-time lower risk of developing the condition, compared to patients not on a GLP1RA medication.
“Our findings show that HTG is not a reason to withhold this class of medication from appropriate patients, if they would benefit otherwise,” she said. “This is an important finding that helps enhance out treatment options.”
Iverson added that clinicians are also seeing triglyceride levels in patients go down because of being on GLP1RA medications. This makes sense, she said, as GLP1RAs address issues like diabetes and obesity that can raise triglyceride levels.
###
END
Weight loss drugs don’t increase the risk of pancreatitis or adverse cardiac events in patients with high triglycerides
2025-11-09
ELSE PRESS RELEASES FROM THIS DATE:
Major international study confirms that beta-blockers are no longer needed in post-infarction patients with normal heart function
2025-11-09
A major analysis led by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), in collaboration with international institutions, has pooled data from 17,801 myocardial infarction survivors with preserved cardiac function enrolled in five global clinical trials. The study concludes that beta-blockers offer no clinical benefit for this patient group, which today represents the majority of infarction survivors. The study was made possible by close collaboration between CNIC researchers and the ...
Targeted vitamin D3 supplementation cuts risk of heart attack patients having a second heart attack in half, new intermountain health study finds
2025-11-09
A tailored approach of vitamin D3 supplementation in patients who have suffered a heart attack significantly reduces their risk of a second heart attack, a new study from heart researchers at Intermountain Health in Salt Lake City finds.
In a large, randomized clinical trial, Intermountain Health researchers have found that treating heart attack patients in a “target to treat” fashion, where patients’ blood levels of vitamin D were monitored and vitamin D3 dosing adjusted to achieve optimal levels, cut their risk of a second heart attack in half.
Results of the study were presented on Nov. 9 at the 2025 American Heart Association Scientific ...
Any form of hypertension during pregnancy significantly increases postpartum cardiovascular risk including death, new study finds
2025-11-09
A new study from researchers at Intermountain Health reveals that hypertensive disorders of pregnancy (HDP) significantly increase the risk of cardiovascular complications — including heart attack, stroke, heart failure, and death — within five years of giving birth.
The study found that women who experienced HDP during pregnancy were significantly more likely to develop serious cardiovascular-related issues compared to those without HDP. These findings underscore the growing body of evidence over the past two decades linking pregnancy-related hypertension to ...
Opening all blocked arteries with stents reduces risk of death from cardiovascular causes compared with opening only the culprit artery in heart attack patients
2025-11-09
Opening all blocked arteries with stents in patients with a heart attack, known as complete revascularization, reduces the risk of death from cardiovascular causes, death from any cause and future heart attacks compared with opening only culprit artery causing the heart attack according to a new, large international study led by researchers at the Population Health Research Institute (PHRI), a joint organization of McMaster University and Hamilton Health Sciences.
The results were published simultaneously in The Lancet and presented in a Late-Breaking Clinical Science Featured Research ...
More prenatal visits linked to right level of care for infants born with heart defects
2025-11-09
In cases of mild congenital heart defects, more prenatal visits are associated with greater likelihood of appropriate delivery at a community hospital, according to a study published in JAMA Network Open. Results suggest that more prenatal care is beneficial for families and may allow their newborns with mild heart defects to receive the right level of care closer to home, as opposed to traveling to a regional cardiac surgical center, which can be expensive, taxing and stressful for families.
Congenital heart defects are the most common and resource-intensive birth defects in the United States. Infants with the most complex heart defects are usually directed ...
Drink Up: Coffee is safe for people with A-Fib
2025-11-09
Drinking coffee can protect against atrial fibrillation (A-Fib), a common heart rhythm disorder that causes rapid, irregular heartbeat and can lead to stroke and heart failure.
Doctors typically recommend that people with heart issues like A-Fib avoid caffeine out of fear that it will trigger symptoms. But a study by UC San Francisco and the University of Adelaid has concluded that drinking a cup of caffeinated coffee a day reduced A-Fib by 39%.
“Coffee increases physical activity which is known to reduce atrial fibrillation,” said Gregory M. Marcus, MD, MAS, ...
Study reports on global trends in acute kidney injury– related mortality
2025-11-08
Houston, TX (November 8, 2025) — A 5-year study revealed a stability of globalacute kidney injury (AKI)–related mortality rates with differing patterns that indicate a rising concentration of mortality in older populations and higher socioeconomiccountries. The findings will be presented at ASN Kidney Week 2025 November 5– 9.
When investigators at the Kyung Hee University Hospital in Seoul assessed AKI-related mortality trends in 43 countries from 1996–2021 using the WHO MortalityDatabase, they ...
Study reveals a potentially better way to optimize the timing for kidney transplant waitlisting
2025-11-08
Houston, TX (November 8, 2025) — The current kidney transplant waitlistingcriterion is based on a single measurement of kidney function (estimated glomerular filtration rate [eGFR] ≤20 ml/min/1.73m2) and does not consider an individual’s risk of progressing to kidney failure. A new study reveals that inclusion of a patient’s 2-year risk of progression to kidney failure (using theKidney Failure Risk Equation [KFRE], which incorporates age, ...
Transitional dialysis program in Texas decreased the use of emergency dialysis
2025-11-08
Houston, TX (November 8, 2025) — The cost of emergency dialysis is estimated to be 8-times that of in-center dialysis. A new study reveals that a transitional dialysis program piloted in Travis County (Austin, TX) resulted in a significant decrease in emergency department visits and hospital admissions for emergency dialysis by providing a pathway for outpatient dialysis in uninsured patients. Thefindings will be presented at ASN Kidney Week 2025 November 5– ...
Quality improvement intervention may help prevent deaths from metformin-associated lactic acid
2025-11-08
Houston, TX (November 8, 2025) — Metformin-associated lactic acidosis(MALA) is a rare but serious adverse effect of the diabetes drug metformin in which the body accumulates too much lactic acid. Investigators developed and tested a protocol for diagnosis and treatment of MALA. Their work will be presented at ASN Kidney Week 2025 November 5– 9.
The protocol, which included immediate initiation of dialysis using either intermittent hemodialysis, continuous kidney replacement therapy, or peritonealdialysis as treatment, ...